Wednesday 20 May 2026

One To Watch

Lykos Therapeutics

A public benefit corporation (PBC) developing investigational psychedelics to catalyze therapeutic approaches for mental health conditions.

Company Overview

Want to Update your Company's Profile?


Latest Lykos Therapeutics News

Change of CEO next for rejection-rocked Lykos
6 September 2024
Lykos reorganizes after midomafetamine setback
16 August 2024
FDA slaps CRL on Lykos Therapeutics’ midomafetamine NDA
12 August 2024
The week in pharma: action, reaction and insight – week to June 7, 2024
9 June 2024
More Lykos Therapeutics news >


Today's issue

Edison’s AI scientist to be embedded across Incyte discovery and development ops
Pharmaceutical
Edison’s AI scientist to be embedded across Incyte discovery and development ops
20 May 2026
Biotechnology
Artiva names Diego Miralles as president and head of R&D
20 May 2026
Biotechnology
AMR Bio launches with Phase III-ready antimicrobial
20 May 2026
Pharmaceutical
Supreme Court rejects bid to halt IRA price negotiations
20 May 2026
Pharmaceutical
Dysport edges Botox on durability in spasticity head-to-head
20 May 2026
Pharmaceutical
WHO declares Ebola outbreak global emergency
20 May 2026
Biotechnology
Mentari lists via InMed merger, takes $290m for migraine pipeline
20 May 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze